{"title":"免疫功能低下儿童患者的IVIG治疗进展与前景?","authors":"K. Derwich","doi":"10.26420/annhematoloncol.2018.1224","DOIUrl":null,"url":null,"abstract":"Continuous development of effective antineoplastic therapies causes that immunodeficiencies are estimated to be one of the most vital problem of treatment. One of the possible keys for that could be Intravenous Immunoglobulins (IVIGs), but recommendations about substitution are not straightforward. if 4-5g/L is introduce a of pediatric patients with lack of unequivocal guidelines both should orientated in a role of on therapies and prevention for pediatric hemato-oncology","PeriodicalId":72219,"journal":{"name":"Annals of hematology & oncology","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2018-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"IVIG in Immunocompromised Pediatric Patients - Advances and Prospects?\",\"authors\":\"K. Derwich\",\"doi\":\"10.26420/annhematoloncol.2018.1224\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Continuous development of effective antineoplastic therapies causes that immunodeficiencies are estimated to be one of the most vital problem of treatment. One of the possible keys for that could be Intravenous Immunoglobulins (IVIGs), but recommendations about substitution are not straightforward. if 4-5g/L is introduce a of pediatric patients with lack of unequivocal guidelines both should orientated in a role of on therapies and prevention for pediatric hemato-oncology\",\"PeriodicalId\":72219,\"journal\":{\"name\":\"Annals of hematology & oncology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-12-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of hematology & oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.26420/annhematoloncol.2018.1224\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of hematology & oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26420/annhematoloncol.2018.1224","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
IVIG in Immunocompromised Pediatric Patients - Advances and Prospects?
Continuous development of effective antineoplastic therapies causes that immunodeficiencies are estimated to be one of the most vital problem of treatment. One of the possible keys for that could be Intravenous Immunoglobulins (IVIGs), but recommendations about substitution are not straightforward. if 4-5g/L is introduce a of pediatric patients with lack of unequivocal guidelines both should orientated in a role of on therapies and prevention for pediatric hemato-oncology
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
